A federal advisory committee to the US Centers for Disease Control and Prevention (CDC) has recommended that all Americans—including children, pregnant women, and adults—receive single-dose influenza vaccines that do not contain thimerosal, a mercury-based preservative long scrutinized despite decades of safe use. This move, which could soon lead to an official CDC policy, reflects an ongoing international spotlight on vaccine ingredients and the public’s persistent concern over vaccine safety—a topic with direct relevance for Thailand’s immunization practices and public confidence.
Thimerosal’s role in medical practice, especially in vaccines, has been under periodic public and regulatory scrutiny, surfacing often in debates about mercury exposure and the origins of autism, despite overwhelming scientific evidence debunking a link. The CDC’s advisory panel, newly restructured by the US Health Secretary, held its first meeting with a new cohort of seven members and placed the thimerosal issue at the top of the agenda. Their recommendations were based not on evidence of harm but on a desire to respond to public pressures and simplify vaccine policy. According to the US Food and Drug Administration (FDA), thimerosal has “a long record of safe and effective use” as a preservative.
Thimerosal, used since the 1930s, contains about 50% mercury by weight. However, the compound is not methylmercury—the toxic form found in seafood and responsible for many of mercury’s health warnings—but ethylmercury, which is quickly eliminated by the human body. Thimerosal’s principal function is to prevent contamination in multi-dose vials of vaccines, ensuring safety when multiple doses are drawn from the same vial. In recent years, this preservative has nearly disappeared from most flu vaccines; in the 2024-25 flu season, 94% of flu shots in the US were thimerosal-free or contained only reduced amounts of the preservative (NPR).
According to the chief clinical officer of the Association of Immunization Managers, thimerosal remains practical in certain healthcare settings where refrigeration space is limited, and multi-dose vials are more affordable and straightforward to store than single-dose syringes. However, the market for thimerosal-containing vaccines has contracted dramatically, making a full transition logistically manageable. Leading vaccine manufacturers, including Sanofi and Seqirus, confirmed that multi-dose vials containing thimerosal constitute only a small fraction of their current supply, with both companies promising smooth transitions to single-dose vials without noticeable impact on supply or shipment timing for the coming season.
Despite persistent claims raised since the late 1990s about a purported link between thimerosal and autism, decades of studies show no association. As the former chief scientist at the FDA (now based at Georgetown University) and numerous reviews by the US National Academies and the Centers for Disease Control and Prevention have repeatedly confirmed, thimerosal is not associated with autism or neurological harm. Notably, as highlighted by Georgetown’s FDA specialist, rates of autism have continued to rise globally in recent decades—even as thimerosal has been removed from vaccines—undermining any causal link (CDC, National Academies of Sciences). This situation mirrors Thailand’s own experiences with vaccine skepticism and the challenge of correcting public misinformation.
Thailand’s national immunization program stopped using multi-dose vials with thimerosal in nearly all routine childhood vaccines after 2001, following World Health Organization (WHO) recommendations and in line with similar moves in the US and Europe (WHO). However, influenza vaccination in Thailand still sometimes uses multi-dose vials, especially for adult and risk-group immunization campaigns during flu season, due to cost and storage considerations. As the US moves to phase out thimerosal completely, there may be international pressure—including from procurement contracts and global health agencies—to adopt single-dose formats exclusively. While the risk to public health remains theoretical, the need to ensure ongoing public trust is pressing, particularly when misinformation about vaccine safety persists widely on social media platforms in both the US and Thailand.
The broader context for this shift can be traced to the aftermath of a now-discredited 1998 publication claiming a link between vaccines and autism. That research, which focused on the MMR (measles, mumps, rubella) vaccine and not thimerosal, was later exposed as fraudulent. Yet, echoes of those unsubstantiated fears have swelled into wider vaccine hesitancy movements, occasionally making parents wary of all vaccine ingredients, regardless of scientific consensus (BMJ). As a former ACIP (Advisory Committee on Immunization Practices) member told NPR, responding to such misplaced concerns by banning thimerosal may undermine rather than strengthen public confidence by appearing to validate baseless fears: “The risk from influenza is so much greater than the non-existent, as far as we know, risk from thimerosal. There is no scientific evidence that thimerosal has caused a problem.”
For Thailand, where vaccine acceptance remains generally high but pockets of hesitancy exist—particularly in connection to imported vaccines or unfamiliar brands—transparency and clarity are crucial. Health authorities often rely on guidelines from international agencies, including the WHO, UNICEF, and leading national health agencies. Moves such as the CDC’s could indirectly push Thai health policymakers and hospital administrators to review procurement policies, prioritizing single-dose vaccine purchases even if multi-dose vials are more cost-effective and logistically flexible for some local clinics, especially in rural Northern or Northeastern provinces with limited cold chain storage.
From a cultural and historical perspective, Thailand has successfully managed several vaccine transitions in the past, from oral to injectable polio vaccines and from whole-cell to acellular pertussis, often by focusing on public education campaigns, endorsements from respected Thai medical associations, and televised appearances by doctors attached to prominent teaching hospitals. However, experience with COVID-19 vaccine misinformation highlighted the persistent risks of social media amplification of fringe theories—a lesson that resonates strongly with recent US vaccine politics.
Looking forward, if the CDC adopts the ACIP recommendations, small logistical ripples could follow for vaccine manufacturers, potentially driving up costs for flu campaigns globally but simplifying messaging for the public (“all vaccines are thimerosal-free”). For Thailand, this may mean working closely with regional suppliers and international donors to ensure continuity of supply and avoid disruptions during seasonal peaks, especially for vulnerable populations such as the elderly and frontline healthcare workers.
The practical recommendation for Thai readers—especially parents and public health officials—is not to let ingredient debates distract from the real threat posed by influenza itself. Major Thai and global health authorities agree that the benefits of annual flu vaccination far outweigh any theoretical risks from long-studied preservatives. Asking for single-dose syringes at local clinics is unlikely to be necessary, as the vast majority of available vaccines are already thimerosal-free. Nevertheless, awareness and dialogue with healthcare providers about vaccine options can help maintain public confidence in immunization and support Thailand’s strong record in disease prevention.
For those looking to learn more or engage with the issue, the best course is to follow reputable sources such as the Department of Disease Control Thailand, the World Health Organization, and internationally recognized science news outlets. Practical action, like ensuring annual flu shots for the whole family and staying informed about official health communications, will help Thai society protect itself against both disease and misinformation.
Sources: NPR, CDC, WHO, BMJ, National Academies of Sciences